Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].
Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis DJ, Braaf L, Broeks A, Kerkhoven R, van Kessel KEM, Ribal MJ, Alcaraz A, Wessels LFA, Seiler R, Wright JL, Mengual L, Boormans J, van Rhijn BWG, Black PC, van der Heijden MS. Gil-Jimenez A, et al. Among authors: contreras sanz a. Eur Urol. 2023 Jun;83(6):e165. doi: 10.1016/j.eururo.2023.03.002. Epub 2023 Mar 10. Eur Urol. 2023. PMID: 36907692 No abstract available.
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis DJ, Braaf L, Broeks A, Kerkhoven R, van Kessel KEM, Ribal MJ, Alcaraz A, Wessels LFA, Seiler R, Wright JL, Mengual L, Boormans J, van Rhijn BWG, Black PC, van der Heijden MS. Gil-Jimenez A, et al. Among authors: contreras sanz a. Eur Urol. 2023 Apr;83(4):313-317. doi: 10.1016/j.eururo.2022.07.023. Epub 2022 Aug 11. Eur Urol. 2023. PMID: 35965206
Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine.
Tsukahara S, Shiota M, Takamatsu D, Nagakawa S, Matsumoto T, Kiyokoba R, Yagi M, Setoyama D, Noda N, Matsumoto S, Hayashi T, Contreras-Sanz A, Black PC, Inokuchi J, Kohashi K, Oda Y, Uchiumi T, Eto M, Kang D. Tsukahara S, et al. Among authors: contreras sanz a. Sci Rep. 2022 May 20;12(1):8535. doi: 10.1038/s41598-022-12528-3. Sci Rep. 2022. PMID: 35595780 Free PMC article.
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. Chou J, et al. Among authors: contreras sanz a. Eur Urol Oncol. 2022 Dec;5(6):714-718. doi: 10.1016/j.euo.2021.11.005. Epub 2022 Feb 23. Eur Urol Oncol. 2022. PMID: 35216942 Free PMC article.
21 results